Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.

Slides:



Advertisements
Similar presentations
1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.
Advertisements

Hepatitis C Treatment in Corrections: New Medicine, New Challenges
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Medicaid Maximization & Criminal Justice Involved Individuals
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
" The Impact of Criminal Justice Policies and Practices on Minorities" 2009.
Patrizia FARCI. Hepatitis Delta Virus Hepatitis B surface antigen (HBsAg) HDV RNA genome Hepatitis delta antigen (HDAg) 36 nm From HDV: From HBV: From.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.
Hepatitis C In Alaska’s Department of Corrections
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Hep 202 Just when you thought you knew everything.
H EALTH INEQUALITIES IN THE NEW EU MEMBER STATES AND CANDIDATE COUNTRIES.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
Management of Hepatitis C: An Unprecedented Challenge for Corrections Brad Livingston Executive Director, Texas Department of Criminal Justice Lannette.
Hepatitis B and C: A silent but deadly epidemic Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Richmond, Virginia.
Healthy Aging & Participating in Research. Discoveries from research led to the medicines and treatments we take for granted today: Vaccines to prevent.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Quality in Laboratory Medicine Conference Business Case for Quality Recognizing Excellence in Practice Presented to the Institute for Quality in Laboratory.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Wyoming Department of Health Communicable Diseases
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Public Safety, Public Spending: F orecasting America’s Prison Population, Adam Gelb, Project Director Public Safety Performance Project The Pew.
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
The Lancet. Infectious diseases. June 2015, PMID:
Tackling hepatitis C - what PHE modelling shows us Helen Harris BSc PhD FFPH LJWG meeting; November 2014.
U.S. Drug Costs Dropped in 2012, but Rises Loom Katie Thomas The New York Times March 18, 2013
Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
Health Care Reform in America. The Stats 47 million people in the US do not have health insurance 792,000 people in CO do not have insurance – 1/5 of.
Hepatitis C: Where are we? Where do we want to go?
HEPATITIS C Kimberly Klatt. CHARACTERISTICS  Virus  Enveloped  Single-stranded RNA virus  High mutation rate  6 different genotypes  Most cases.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
LIVER HEALTH an integral part of CF gastrointestinal care Zachary M Sellers, MD, PhD Fellow Pediatric Gastroenterology, Hepatology, and Nutrition Stanford.
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
Template ID: junglegreens Size: 36x48 Impact of Hepatitis C Screening in Outpatient Population Madhuri Chandnani MD, Pallavi Pothuri MD, Michael Stevens.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
The changing landscape of hepatitis infection
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
Phase 3 Treatment-Naïve and Treatment-Experienced
Treatment Outcomes for Chronic Hepatitis C Infection with Direct Acting Antivirals among Inmates in Federal Corrections Smith JM, Boudreau H, Kom E, Tremblay.
BACKGROUND MATERIALS & METHODS RESULTS CONCLUSIONS
Core Competency 4: HCV Treatment
Talking to Patients About HCV Treatment
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
Treating Hep C with Novel Agents
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
Figure 1 Patients cured of HCV infection
New Opportunities in Medicare
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
Management of cirrhosis due to chronic hepatitis C
Volume 61, Issue 3, Pages (September 2014)
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Managing Hepatitis C in Vermont
Presentation transcript:

Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections

USA TODAY, March 2014 Should prisoners get expensive hepatitis C drugs? Michael Ollove, Pew/Stateline Staff Writer

The Issue At Hand The new treatment regimens for Hepatitis are tantamount to a cure for the disease The new treatment regimens present minimal side effects and are very well tolerated The cost of the new treatment per inmate is $84000-$160,000. Available financial resources result in the prioritization of patients for treatment

The Wisconsin Approach Try to mirror the treatment practices applied to other prison populations and the community ▫University of Wisconsin ▫Federal Bureau of Prisons ▫American Association for the Study of Liver Diseases (AASLD) ▫Infectious Diseases Society of America (IDSA)

The Wisconsin Approach Identify the patients with advanced disease ▫These patients have a higher risk of complications from Hepatitis C if not treated  Cirrhosis  Liver cancer ▫Patients are selected based on:  Degree of liver fibrosis (Metavir F3 or F4)  Other complicating factors: liver transplant, hepatitis induced kidney disease or vasculitis  Evidence of liver failure

The Wisconsin Approach Our screening will lead to a possible referral to the University of Wisconsin Hepatology experts. UW Hepatology will help determine who ultimately needs the treatment now. All patients will be treated with the new medications (≈ $1000 per day). Those who do not need the treatment now will be monitored closely using the same screening criteria and referred for treatment when indicated.

Percentage of Patients with Hep C

Some Wisconsin Data Prior to July 2014 ▫Patients with genotype 2 (because of their typically good response to treatment) and those with lesser degrees of fibrosis received treatment if they could tolerate the side effects ▫Treatment consisted of combinations of Pegylated Interferon, Ribavirin and Telaprevir depending on their genotype ▫Averaged 100 treatments per year ▫Significant drop out rate because of side effects

Previous Cost of Treatment

Estimates Going Forward Wisconsin DOC population is around 22,000 inmates 16 % estimated to have Hepatitis C ≈ 3520 inmates Estimated number with advanced (Metavir F3) disease ≈ 1056 (30%) Cost if all with advanced disease are treated…

$ Million Dollars

Since Money Doesn’t Grow on Trees.. On average over the past few years we treated 100 patients per year. Estimate to treat about 30 per year (those with advanced fibrosis) using the new treatments. Estimated cost of $3-4 million per year using the new treatments. The current budget did not account for this rise in pharmacy costs.

Questions Going Forward Will the cost of the treatments increase before competition lowers them? ▫When will costs go down? Will the courts determine the standard of care and treatment going forward? ▫Will they mandate everyone receives treatment with the new drugs? How will we find the resources to address the above questions?

Thank You